Aztreonam Dosing and Indications
Aztreonam is a monobactam antibiotic indicated for gram-negative infections including hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), urinary tract infections, and severe systemic infections, with dosing that must be adjusted based on renal function: 500 mg to 2 g IV every 6-12 hours for normal renal function, halved for moderate impairment (CrCl 10-30 mL/min), and reduced to one-fourth for severe impairment (CrCl <10 mL/min) after an initial loading dose. 1
Primary Indications
Aztreonam provides antipseudomonal gram-negative coverage and is specifically recommended in the 2016 IDSA/ATS guidelines for empiric treatment of VAP when double gram-negative coverage is warranted. It serves as an alternative monobactam option at 2 g IV every 8 hours for empiric VAP treatment 2. A unique advantage: aztreonam can be combined with other β-lactams because it targets different bacterial cell wall sites, making it acceptable as adjunctive therapy when other options are limited 2.
The drug achieves therapeutic levels against:
- Pseudomonas aeruginosa (MIC₉₀ coverage for 4-6 hours with 2 g dose)
- Neisseria species and Haemophilus influenzae (8-hour coverage)
- Most Enterobacteriaceae (8-hour coverage for 80-90% of strains) 1
Dosing for Normal Renal Function
For adults with normal renal function (CrCl >30 mL/min):
- Urinary tract infections: 500 mg or 1 g IV every 8-12 hours
- Moderately severe systemic infections: 1 g or 2 g IV every 8-12 hours
- Severe/life-threatening infections or Pseudomonas infections: 2 g IV every 6-8 hours 1
The intravenous route is mandatory for:
- Doses exceeding 1 g
- Bacterial septicemia
- Localized abscesses (e.g., intra-abdominal)
- Peritonitis
- Other severe systemic infections 1
Critical pharmacokinetic parameters: Half-life averages 1.7 hours in normal renal function, with 60-70% urinary excretion by 8 hours and essentially complete elimination by 12 hours 1.
Moderate Renal Impairment (CrCl 10-30 mL/min)
After an initial loading dose of 1 g or 2 g, reduce the maintenance dose to one-half the usual dose at the standard interval 1. For example:
- If standard dose is 2 g every 8 hours → give 2 g loading, then 1 g every 8 hours
- If standard dose is 1 g every 8 hours → give 1 g loading, then 500 mg every 8 hours
Recent population pharmacokinetic modeling confirms this approach maintains >90% probability of target attainment (60% fT>MIC) for MICs up to 4-8 mg/L 3. For patients in the CrCl 31-50 mL/min range, both every 6-hour and every 8-hour regimens with 2-3 hour infusions achieve acceptable target attainment 4.
Severe Renal Impairment (CrCl <10 mL/min)
Give the usual initial dose (500 mg, 1 g, or 2 g), then reduce maintenance to one-fourth of the initial dose at the usual interval (every 6,8, or 12 hours) 1.
For hemodialysis patients: After each dialysis session, administer an additional one-eighth of the initial dose, as aztreonam is efficiently cleared by hemodialysis 1, 5.
Simplified alternative for end-stage renal disease: Monte Carlo simulations support 1-2 g administered once daily after hemodialysis as a practical regimen with >90% target attainment for MICs ≤4-8 mg/L, avoiding the complexity of the labeled regimen 6. Thrice-weekly dosing should be avoided except for non-severe infections with MICs ≤0.5 mg/L 6.
For CrCl 15-30 mL/min: An exploratory simplified regimen of 0.75 g every 8 hours over 2 hours (half-vial dosing) provides comparable target attainment to complex labeled regimens 4.
Calculating Creatinine Clearance
When only serum creatinine is available (representing steady-state renal function):
Males: CrCl = [weight (kg) × (140 - age)] / [72 × serum creatinine (mg/dL)]
Females: 0.85 × male calculation 1
Critical caveat: Elderly patients may have diminished renal function despite normal serum creatinine. Always estimate creatinine clearance rather than relying on serum creatinine alone 1.
Treatment Duration
Continue aztreonam for at least 48 hours after the patient becomes asymptomatic or bacterial eradication is documented. Persistent infections may require several weeks of therapy 1. The 2016 IDSA/ATS guidelines emphasize that empiric regimens should be narrowed based on culture results and local antibiograms 2.
Infusion Considerations
For patients with CrCl >80 mL/min requiring VAP treatment, 3-hour infusions are most robust; shortening to 1-2 hours reduces target attainment 4. However, for CrCl 31-80 mL/min, 2-hour infusions are reasonable alternatives that improve practicality without compromising efficacy 4.
Special Populations
Pediatric patients (≥1 month to 12 years):
- Mild-moderate infections: 30 mg/kg IV every 8 hours
- Moderate-severe infections: 30 mg/kg IV every 6-8 hours
- Maximum: 120 mg/kg/day
- IV route only; insufficient data for IM dosing or renal impairment adjustments 1
Hepatic impairment: No dose adjustment needed; the liver is a minor elimination pathway 1.
Common Pitfalls
Failing to give a loading dose in renal impairment: The serum half-life increases from 2 hours (normal) to 6 hours (anephric patients) 7. Without a loading dose, therapeutic levels are delayed.
Using serum creatinine alone in elderly patients: Age-related renal decline may not elevate creatinine; always calculate CrCl 1.
Underdosing during rapid AKI recovery: As renal function improves, drug clearance increases. TDM-guided dose escalation prevents treatment failure 8.
Overlooking CVVHDF clearance: Continuous renal replacement therapy significantly clears aztreonam (mean clearance 1.28 L/h) and avibactam (2.08 L/h), with filter type affecting exposure 8.